Condition: Waldenström Macroglobulinemia · Lymphoplasmacytic Lymphoma · B-Cell Lymphoproliferative Disorder · Sponsor: Shayna Sarosiek, MD
This study is being done to examine the safety and effectiveness of pacritinib as a possible treatment for participants with Waldenström macroglobulinemia (WM). The name of the study drug involved in this study is: -Pacritinib (a type of kinase inhibitor)
This description comes directly from the study's public registry record.
Shayna Sarosiek, MD · 617-632-4218 · Shayna_Sarosiek@dfci.harvard.edu
Always discuss trial participation with your own doctor first.
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06986174